Free Trial

Bolt Biotherapeutics (BOLT) Competitors

Bolt Biotherapeutics logo
$0.32 +0.01 (+2.52%)
Closing price 05/22/2025 04:00 PM Eastern
Extended Trading
$0.31 -0.01 (-3.38%)
As of 07:42 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BOLT vs. CRIS, SABS, MTEM, AMGN, GILD, VRTX, REGN, ALNY, BIIB, and UTHR

Should you be buying Bolt Biotherapeutics stock or one of its competitors? The main competitors of Bolt Biotherapeutics include Curis (CRIS), SAB Biotherapeutics (SABS), Molecular Templates (MTEM), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), and United Therapeutics (UTHR). These companies are all part of the "biotechnology" industry.

Bolt Biotherapeutics vs.

Bolt Biotherapeutics (NASDAQ:BOLT) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their community ranking, dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

86.7% of Bolt Biotherapeutics shares are owned by institutional investors. Comparatively, 30.0% of Curis shares are owned by institutional investors. 6.1% of Bolt Biotherapeutics shares are owned by insiders. Comparatively, 5.7% of Curis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Curis had 2 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 6 mentions for Curis and 4 mentions for Bolt Biotherapeutics. Bolt Biotherapeutics' average media sentiment score of 0.67 beat Curis' score of 0.56 indicating that Bolt Biotherapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bolt Biotherapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Curis
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Curis has a net margin of -443.35% compared to Bolt Biotherapeutics' net margin of -665.56%. Bolt Biotherapeutics' return on equity of -69.46% beat Curis' return on equity.

Company Net Margins Return on Equity Return on Assets
Bolt Biotherapeutics-665.56% -69.46% -48.55%
Curis -443.35%-923.37%-78.35%

Bolt Biotherapeutics presently has a consensus target price of $2.50, indicating a potential upside of 669.23%. Curis has a consensus target price of $17.00, indicating a potential upside of 754.27%. Given Curis' stronger consensus rating and higher possible upside, analysts plainly believe Curis is more favorable than Bolt Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bolt Biotherapeutics
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33
Curis
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Bolt Biotherapeutics has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Comparatively, Curis has a beta of 3.65, suggesting that its share price is 265% more volatile than the S&P 500.

Curis received 614 more outperform votes than Bolt Biotherapeutics when rated by MarketBeat users. Likewise, 67.28% of users gave Curis an outperform vote while only 63.28% of users gave Bolt Biotherapeutics an outperform vote.

CompanyUnderperformOutperform
Bolt BiotherapeuticsOutperform Votes
81
63.28%
Underperform Votes
47
36.72%
CurisOutperform Votes
695
67.28%
Underperform Votes
338
32.72%

Curis has higher revenue and earnings than Bolt Biotherapeutics. Curis is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bolt Biotherapeutics$3.64M3.43-$69.20M-$1.67-0.19
Curis$11.20M1.86-$47.41M-$6.23-0.32

Summary

Curis beats Bolt Biotherapeutics on 9 of the 17 factors compared between the two stocks.

Get Bolt Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BOLT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BOLT vs. The Competition

MetricBolt BiotherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$12.15M$6.47B$5.33B$8.39B
Dividend YieldN/A2.64%5.21%4.10%
P/E Ratio-0.199.0626.7519.70
Price / Sales3.43259.83392.41121.79
Price / CashN/A65.8538.2534.62
Price / Book0.116.456.774.50
Net Income-$69.20M$143.98M$3.23B$248.22M
7 Day Performance10.92%0.38%0.43%-0.80%
1 Month Performance-12.63%2.14%9.07%11.52%
1 Year Performance-58.04%-0.33%18.59%8.99%

Bolt Biotherapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BOLT
Bolt Biotherapeutics
3.2445 of 5 stars
$0.33
+2.5%
$2.50
+669.2%
-57.5%$12.15M$3.64M-0.1990Analyst Forecast
High Trading Volume
CRIS
Curis
3.0564 of 5 stars
$2.08
+2.5%
$17.00
+717.3%
-81.6%$21.76M$11.20M-0.2760Analyst Revision
Gap Up
SABS
SAB Biotherapeutics
2.855 of 5 stars
$1.80
-2.7%
$12.20
+577.8%
-32.9%$16.73M$2.24M-0.49140
MTEM
Molecular Templates
N/AN/AN/AN/A$1,000.00$23.48M0.00260
AMGN
Amgen
4.3708 of 5 stars
$275.85
+1.3%
$310.18
+12.4%
-12.1%$148.33B$34.13B36.5425,200Positive News
Analyst Forecast
GILD
Gilead Sciences
4.6504 of 5 stars
$106.16
+3.6%
$110.55
+4.1%
+57.4%$132.06B$28.74B286.9217,000Positive News
Analyst Forecast
Options Volume
VRTX
Vertex Pharmaceuticals
4.6184 of 5 stars
$440.66
+0.5%
$515.04
+16.9%
-3.0%$112.64B$11.10B-200.304,800Positive News
REGN
Regeneron Pharmaceuticals
4.7898 of 5 stars
$596.54
+0.4%
$890.60
+49.3%
-39.3%$64.41B$14.09B15.5811,900Dividend Announcement
Ex-Dividend
ALNY
Alnylam Pharmaceuticals
4.1825 of 5 stars
$291.86
+2.3%
$319.17
+9.4%
+91.5%$38.06B$2.35B-134.502,000Positive News
BIIB
Biogen
4.8956 of 5 stars
$129.44
+3.1%
$191.30
+47.8%
-43.9%$18.97B$9.82B11.578,720Positive News
UTHR
United Therapeutics
4.9794 of 5 stars
$305.31
0.0%
$392.00
+28.4%
+11.7%$13.77B$2.99B13.41980Positive News
Analyst Revision

Related Companies and Tools


This page (NASDAQ:BOLT) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners